Immunogenicity of trivalent influenza vaccine in patients with lung cancer undergoing anticancer chemotherapy.
Lung cancer is a leading cause of cancer-related death, and patients with lung cancer are a priority group for influenza vaccination. However, few studies have assessed the immunogenicity of the influenza vaccine in these patients. Here, we performed a prospective study to evaluate the immunogenicity of the influenza vaccine in patients with lung cancer undergoing anticancer chemotherapy. Twenty-five patients with lung cancer undergoing anticancer chemotherapy and 26 patients with chronic obstructive pulmonary disease (COPD) as controls were enrolled. A trivalent influenza vaccine containing inactivated A/California/7/2009 (H1N1) pdm09, A/Texas/50/2012 (H3N2), and B/Massachusetts/2/2012 was administered as a single subcutaneous injection. Serum samples were collected before vaccination, and at 4-6 weeks after vaccination. Levels of serum antibody to hemagglutinin were measured. Among patients with lung cancer, the seroprotection rate (postvaccination titer > 1:40) was 84% for both A(H1N1) and A(H3N2), similar to the levels observed in patients with COPD. However, the seroprotection rate for the B strain was significantly lower in patients with lung cancer than in patients with COPD (64% versus 92%). Even after adjustment for potential confounders, patients with lung cancer had a significantly lower odds ratio for seroprotection against the B strain than patients with COPD. Moreover, in patients with lung cancer, those receiving the platinum doublet treatment tended to exhibit a lower seroprotection rate than those receiving a single agent. Thus, patients with lung cancer undergoing anticancer chemotherapy showed acceptable immune responses to a trivalent influenza vaccine, supporting the recommendation for annual influenza vaccination in these patients.
a Department of Pulmonary Medicine , Kameda Medical Center , Chiba , Japan.
Kei
K
Nakashima
a Department of Pulmonary Medicine , Kameda Medical Center , Chiba , Japan.
Masahiro
M
Aoshima
b Department of Public Health , Osaka City University Graduate School of Medicine , Osaka , Japan.
Satoko
S
Ohfuji
c Nagoya City University , School of Nursing , Nagoya , Japan.
Kanzo
K
Suzuki
a Department of Pulmonary Medicine , Kameda Medical Center , Chiba , Japan.
Masahiro
M
Katsurada
a Department of Pulmonary Medicine , Kameda Medical Center , Chiba , Japan.
Naoko
N
Katsurada
a Department of Pulmonary Medicine , Kameda Medical Center , Chiba , Japan.
Masafumi
M
Misawa
d Department of Laboratory Medicine , Kameda Medical Center , Chiba , Japan.
Yoshihito
Y
Otsuka
b Department of Public Health , Osaka City University Graduate School of Medicine , Osaka , Japan.
Kyoko
K
Kondo
e College of Healthcare Management , Fukuoka , Japan.
Yoshio
Y
Hirota
D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000097:blood; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology; D053122:Influenza A Virus, H3N2 Subtype / Q000276:immunology; D009981:Influenza B virus / Q000276:immunology; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D007251:Influenza, Human / Q000517:prevention & control*; D008175:Lung Neoplasms / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
D000914:Antibodies, Viral; D000970:Antineoplastic Agents; D007252:Influenza Vaccines
anticancer chemotherapy; chronic obstructive pulmonary disease; immunogenicity; influenza vaccine; lung cancer